

**FULL PAPER**

# Synthesis, characterization, and evaluation of antibacterial and antioxidant activity of 1, 2, 3-triazole, and tetrazole derivatives of cromoglicic acid

Hayfaa A. Mubarak<sup>a</sup>  | Khalida A. Thejeel<sup>b</sup>  | Mustafa M. Karhib<sup>c</sup>  | Mohanad Mousa Kareem<sup>d,\*</sup> <sup>a</sup>Chemical Engineering Department, College of Engineering, University of Babylon, Babylon, Iraq<sup>b</sup>Department of Forensic Evidence, College of Science, Al-Karkh University of Scienc Baghdad, Iraq<sup>c</sup>Department of Medical Laboratory Techniques, Al-Mustaqbal University College, 51001 Hillah, Babylon, Iraq<sup>d</sup>Department of Chemistry, College of Science, University of Babylon, P.O. Box 51002, Hilla, Iraq

The present work includes preparing new compounds of 1, 2, 3-Triazole, and Tetrazole based on Cromoglicic Acid and using them as anti-bacterial and ant-oxidant agents. The mentioned compounds were prepared using click chemistry; triazole rings were reacted with azide (terminal alkyne of cromoglicic acid) in the presence of copper as a catalyst. The modified compounds were characterized using different techniques such as FTIR, <sup>1</sup>H-NMR, and <sup>13</sup>C-NMR. Then, the antioxidant and antibacterial activities of the synthesized compounds were experimentally examined *in vitro* versus two kinds of bacteria (*Escherichia coli* (gram-negative bacteria) and *Staphylococcus aureus* (gram-positive bacteria)). The DPPH (2,2-diphenyl-1-picryl-hydrazyl-hydrate) free radical method was used to measure the antioxidant activity of the prepared compounds, while the antibacterial activity was examined using the diffusion method. The obtained results for all prepared compounds were good as an antioxidant in comparison with ascorbic acid.

**\*Corresponding Author:**

Mohanad Mousa Kareem

E-mail: [mmk.mk2000@gmail.com](mailto:mmk.mk2000@gmail.com)

Tel.: 647817673757

**KEYWORDS**

Azide; triazole rings; anti-oxidant; antibacterial activity.

**Introduction**

Cromoglicic acid (INN), also known as cromolyn (USAN), cromoglycate (old BAN), or cromoglicate, is often marketed as the sodium salt sodium cromoglicate. It is typically characterized as a mast cell stabilizer. Because of its convenience, leukotriene receptor antagonists have essentially taken the place of cromoglicic acid, which was once the non-corticosteroid medication of choice for treating asthma (and perceived safety). Inhaled corticosteroids do not bring any benefits when used with cromoglicic acid, which administered orally four times daily. Cromoglicic acid is used to treat allergies and

conjunctivitis, a surfactant and as atopic dermatitis therapy. It helps heal skin wounds and reduces the risk of pulmonary irritation [1,2]. Because cromoglicic acid is a highly ionized, water-soluble substance, it cannot pass through cell membranes and should be inhaled to be delivered efficiently [2,3].

Although the specific mechanism of action of cromoglicic acid (cromolyn), a medication that is thought to stabilize mast cells, is considerably more complex, it is still thought to have this effect. According to the recent findings, cromolyn inhibits glycogen synthase kinase 3 $\beta$ , which suggests that it may be useful in treating insulin-induced lipotrophy as well as diabetes, obesity, and other

conditions. Agonizing GPR35 has also been reported to have possible anti-fibrotic effects [4-6].

Heterocyclic compounds are natural cyclic compounds with different heteroatoms, including triazole derivatives, which are used in wide fields as herbicides, anti-bacterials, disinfectants, and anti-inflammatory agents [7]. Triazoles are five-member rings that have many important applications such as anti-virus, microbial, and antihistamine. Likewise, have industrial uses such as dyes, agricultural chemicals, and the pharmaceutical industry [8-12]. Cyclic addition reactions are one of the most important types of cyclic reactions used in the synthesis of triazoles from the [2 + 3] cyclic reaction, via two or more unsaturated molecules that are combined to form the triazoles [13-15].

In the present work, we prepared new derivatives having effective groups of 1, 2, 3-triazoles and tetrazole derivatives based on cromoglicic acid, and also their biological activities as antibacterial, and antioxidant were studied.

### Experimental part

#### Materials

The chemical compounds used are from Merck & BDH. The melting point was measured with, "tests eon & Shimadzu (FTIR 8400, Series Japan)" instrument, and also  $^{13}\text{C}$ -NMR,  $^1\text{H}$ -NMR spectra utilizes DMSO- $d_6$  solvent and with "Bruker, Ultra Shield 500-M.HZ Switzerland."

#### Synthesis of compounds (S1) & (S2)[16]

Cromoglicic Acid (S) (0.01 mol, 4.72 gm) dissolved in 50 ml round bottom flask with 25 mL of thionyl chloride and the mix stirred for 15.0 min at room condition. Next, (25 mL) of ethanol and (2 drops) of  $\text{H}_2\text{SO}_4$  were added with reflux for 3 h, and then the solution was concentrated by rotary evaporator and collected to get oil product (S1) and (S2)

white off precipitate compounds, respectively (Scheme 1 and Table 1).

#### Synthesis of compound (S3) [17,18]

(0.01 mol, 4.44 gm) of compound (S2) was added in a round bottom flask and the mixture of hydrazine (0.02 mol, 0.64 gm) and ethanol (40 mL) was added, and then the mixture has been refluxed with stirring for six hours. After that, the precipitate was collected and recrystallized from absolute ethyl alcohol to afford (S3) compound as orange color precipitate (Scheme 1 and Table1).

#### Synthesis of compound (S6, S7) [19]

In 50 ml round bottom flask, (0.02 mol, 7.0 gm, an 7.75 gm) of 3-chlorobenzaldehyde and vanillin were mixed separately with (0.01 mol, 3.56 gm) of S3, and then 20 mL of ethanol and two drops of glacial acetic acid were added to the mixture. After that, the mix was refluxed for 4 h, and then the mix was filtered and the precipitation was collected. TLC technique was applied to follow the reactions. The precipitate recrystallized from absolute ethyl alcohol to afford compounds S6 and S7 as orange and dark yellow respectively (Scheme 1 and Table 1).

#### Synthesis of azide derivative (S8 and S9) [18]

$\text{NaN}_3$  (5 g) was mixed with compound S6 and S7 (0.02 mol.) separately, DMSO (150 mL), and D.W (50.0 mL) in a round bottom flask and stirred at room temperature for 24 hours. The mix was diluted with (200 mL) of D.W, and extracted with diethyl ether (3.0 x 100 mL), the organic layer was collected and dried with  $\text{MgSO}_4$  to get a clear liquid. The solvent was removed using rotary evaporator and the precipitate was purified by recrystallization using ethanol as a solvent to get dark red and white yellow precipitate compounds S8 and S9 respectively (Scheme 1 and Table 1).

*Synthesis of terminal alkynes [S4] [20]*


(20 mmol) of compound (S2) was dissolved in solvent -DMF (60.0 mL), and then K<sub>2</sub>CO<sub>3</sub> (4.0 g), propargyl bromide (2 mL) were added to the mix with stirring and cooling ice bath for 20 minutes. After that, the mixture was stirred for 24 h at 25 C. D.W (120.0 mL) was added to the mixture and extracted by diethyl ether (3.0 x 70 mL). The organic layer was collected and dried with MgSO<sub>4</sub> to get a clear liquid. The solvent was removed by utilizes rotary evaporator to get yellow liquid compound S4 (Scheme 1 and Table 1).

*Synthesis of 1, 2, 3-Triazoles derivatives [S5] [21]*

Compound [S3] (5.30 mmol) was mixed with sodium ascorbate (0.09540 g) and copper sulfate pentahydrate (0.05830 g) in DMSO (5.0 mL). The mixture was stirred for 10 minutes at 60 °C, benzyl azide (5.3 mmol) was added while being heated and stirred for 48 hours. Water (80 mL) was added to the solution and extracted with ethyl acetate three times. The mixture was washed twice in 40 mL of H<sub>2</sub>O, dried with MgSO<sub>4</sub>. The solvent was removed using rotary evaporator and the precipitate was purified by recrystallization using ethanol as a solvent to get reddish brown precipitate compound S5 (Scheme 1 and Table 1).

**TABLE 1** Physical characteristic of derivative (S1-S9)

No.	Color	M. formula	M.Wt	M.P (°C)	Yield %	Rf
S1	Orange	<b>C<sub>23</sub>H<sub>18</sub>Cl<sub>2</sub>O<sub>9</sub></b>	508.08	146-148	70%	0.74( <b>2:8</b> ) DCM:Hexane
S2	Off White	<b>C<sub>27</sub>H<sub>28</sub>O<sub>7</sub></b>	464.18	208-210	89%	0.96( <b>2:8</b> ) DCM:Hexane
S3	Orange	<b>C<sub>23</sub>H<sub>24</sub>N<sub>4</sub>O<sub>7</sub></b>	468.47	118-120	80%	0.81(3:7) DCM:Hexane
S4	Yellow	<b>C<sub>30</sub>H<sub>30</sub>O<sub>7</sub></b>	502.56	Liquid	71%	0.76( <b>2:8</b> ) DCM:Hexane
S5	Reddish Brawn	<b>C<sub>37</sub>H<sub>37</sub>N<sub>3</sub>O<sub>7</sub></b>	635.6	179-181	90%	0.60(1:9) DCM:Hexane
S6	Orange	<b>C<sub>39</sub>H<sub>23</sub>N<sub>4</sub>O<sub>13</sub></b>	764.7	104-106	79%	0.68( <b>2:8</b> ) DCM:Hexane
S7	Dark Yellow	<b>C<sub>37</sub>H<sub>26</sub> Cl<sub>2</sub>N<sub>4</sub> O<sub>9</sub></b>	741.5	Dec>160	84%	0.40(1:9) DCM:Hexane
S8	Dark Red	<b>C<sub>39</sub>H<sub>34</sub>N<sub>9</sub>O<sub>13</sub></b>	850	303-305	88%	0.45(1:9) DCM:Hexane
S9	White yellow	<b>C<sub>38</sub>H<sub>27</sub> Cl<sub>2</sub>N<sub>10</sub> O<sub>9</sub></b>	872	380<	65%	0.56(3:7) DCM:Hexane



**SCHEME 1** Synthesis of compounds (S1-S9)

## Biological activity

### Antibacterial activity

The diffusion method was used to examine the antimicrobial characterization of the prepared compounds and two kinds of bacteria (*Staphylococcus aureus* and *Klebsiella pneumoniae*). The test compounds were doubly diluted across the range of 0.39-50 g/mL after being fully dissolved in dimethyl sulfoxide (DMSO) and placed to a plate (agar medium) at 37.0°C for 24 hours, showed good results (Table 3) [22].

### Antioxidants activity

DPPH (4.0 mg) was utilized by dissolving it in 100.0 mL of CH<sub>3</sub>OH different concentrations (25.0, 50.0, and 1.0 hundred) ppm were

attended. It was soluble in (10.0 mL) of methanol, 3.0 mL of the sample was taken, and 1.0 mL of DPPH was added to it in a tube and left for 30.0 minutes in the dark at 37.0°C, the wave length of antioxidants at 517 nm. The inhibition ratio was calculated using the equation below [23-25].

$$I \% = (\text{Absorption control} - \text{Absorption sample}) / \text{Absorption blank} \times 100$$

## Results and discussion

A new compounds contain functional groups (1, 2, 3-triazoles and tetrazole) based on cromoglicic acid compound have been synthesized (Scheme1) and studied their activity as antibacterial and antioxidant. These compounds were characterized by different techniques.

### Synthesis and characterization of compounds (S3-S9)

The FT-IR spectra for S1 revealed these values ( $V_{max}$ ,  $cm^{-1}$ ): It indicated that the -OH of carboxylic acid was disappeared and the following bands were appeared, 3338 (OH, aliphatic), 3090 (C=CH), 2869 (CH str.), 1765 (C=O), 1612 (C=C), 1230-1309 (C-O, C-N), 780 (C=C=O).  $^1H$ -NMR ( $\delta$  ppm): 2.50 (DMSO), 3.83 (CH<sub>2</sub>), 8.9 (OH), 6.9-7.5 (CH, Ar.). Compound S2, the FT-IR spectrum showed the following values ( $V_{max}$ ,  $cm^{-1}$ ): 3418-3362 (OH), 3091 (C=CH), 2943 (CH str.), 1651 (C=O), 1565 (C=C Aromatic), 1215-1394 (C-N, Aryl).  $^1H$ -NMR (500 MHz,  $\delta$  ppm): 3.8 (CH<sub>2</sub>), 6.9-7.9 (C, Ar.), 7.17 (H, Ethylene), 2.51 (CH<sub>3</sub>, ethane), 3.95 (OH, aliphatic), 2.5 (DMSO). The FT-IR spectrum for S3 shows these values ( $V_{max}$ ,  $cm^{-1}$ ): appeared new bands at 3298 (NH) and 3398 (NH<sub>2</sub>), in addition to 3416 (OH), 3091 (C=CH), 2943 (CH str.), 1651 (N-C=O amid), 1604 (C=C), 1247-1398 (C-O, C-N).  $^1H$ -NMR ( $\delta$  ppm): 2.50 (DMSO), 4.60 (NH<sub>2</sub>), 4.07 (CH<sub>2</sub>), 5.77 (OH), 6.82-7.50 (CH, Ar), 9.44 (NH).  $^{13}C$ -NMR (125 MHz,  $\delta$  ppm): 170.49, 175.40 (C=O), 158.2-107.60 (C-Ar), 68.70 (CH), 71.10 (CH<sub>2</sub>), 40.40 (DMSO). The FT-IR spectrum for S4 revealed these values ( $V_{max}$ ,  $cm^{-1}$ ): 3090 (C=CH), 2945 (CH str.), 1732 (C=O ester), new band at 2342 (HC≡CH), 1602 (C=C), 1265-1334 (C-N).  $^1H$ -NMR ( $\delta$  ppm): 2.51 (DMSO), 3.31 (CH<sub>3</sub>), 4.4-3.9 (CH<sub>2</sub>), 4.7 (CH), 5.87 (OH), 6.82-7.50 (CH, Ar), 3.32 (HC≡CH).  $^{13}C$ -NMR (125 MHz,  $\delta$  ppm): 182.1, 164.7 (C=O), 138.6-108.7 (C, Ar.), 151.3 (C-O), 69.0 (CH), 40.2 (DMSO), 70.01 (CH<sub>2</sub>), 30.7, 29.0 (CH<sub>3</sub>). The FT-IR spectrum of S5 showed these values ( $V_{max}$ ,  $cm^{-1}$ ): 3090 (C=CH), 2983 (CH str.), 1647 (C=O), 1570 (C=C), 1230-1309 (C-N), disappear of HC≡CH and appearance a new band at 1435 (N=N).  $^1H$ -NMR ( $\delta$  ppm): 2.26 (CH<sub>3</sub>), 2.51 (DMSO), 3.9 (NH), 4.07 (CH<sub>2</sub>), 4.6 (CH), 5.7 (OH), 6.82-7.5 (CH, Ar.), 10.06 (NH).  $^{13}C$ -NMR (125 MHz,  $\delta$  ppm): 185.4 (C=O), 137.6-109.1 (C-Ar), 40.4 (DMSO), 69.0 (CH), 72.7 (CH<sub>2</sub>), 31.3 (CH<sub>3</sub>).

The FT-IR spectrum for S6 revealed these values ( $V_{max}$ ,  $cm^{-1}$ ): 2492-3416 (OH, NH), 2995 (CH str.), appearance new band at 1661 (C=N), 1601 (C=C, Ar), 1716 (C=O), 1209.4-1307.70 (C-N).  $^1H$ -NMR ( $\delta$  ppm): 3.90 (OCH<sub>3</sub>), 2.490 (DMSO), 4.40, 4.70 (CH<sub>2</sub>), 8.70 (CH=N), 5.80, 9.540 (OH), 6.82-7.80 (CH, Benzene), 11.20 (NH). The FT-IR spectrum for S7 shows these values ( $V_{max}$ ,  $cm^{-1}$ ): 3494, 3214 (OH, NH), 2914 (CH str.), 3042 (CH, Ar.), 1691 (C=O), appearance new band at 1651 (C=N), 1549 (C=C, Ar), 1209.4-1307.7 (C-N).  $^1H$ -NMR ( $\delta$  ppm): 2.49 (DMSO), 4.5, 4.6 (CH<sub>2</sub>), 8.8 (CH=N), 5.7 (OH), 6.8-7.9 (CH, Benzene), 10.09 (NH). The FT-IR spectrum for S8 revealed these values ( $V_{max}$ ,  $cm^{-1}$ ): 3394, 3390 (OH, NH), 2995 (CH str.), 1718 (C=O), 1608 (C=C, Ar), appearance new band at 1660 (C=N), 1217.4-1419.7 (C-N).  $^1H$ -NMR ( $\delta$  ppm): 3.9 (OCH<sub>3</sub>), 2.49 (DMSO), 4.5, 4.6 (CH), 4.04 (CH<sub>2</sub>), 5.7 (OH, aliphatic), 9.4 (OH, phenol), 6.8-7.5 (CH, Benzene), 12.3 (NH), 4.30 (NH tetrazole).  $^{13}C$ -NMR (125 MHz,  $\delta$  ppm): 182.9, 147.2 (C=O, Carbonyl), 138.3-108.6 (C-benzene), 156, 158 (C-OH), 40.4 (DMSO), 69.06 (CH, aliphatic), 70.09, 72.2 (CH<sub>2</sub> aliphatic), 60 (OCH<sub>3</sub>). The FT-IR spectrum for S9 revealed these values ( $V_{max}$ ,  $cm^{-1}$ ): 3416, 3346 (OH, NH), 2995 (CH str.), 1716 (C=O), 1601 (C=C, Ar), appearance new band at 1665 (C=N), 1209.4-1307.7 (C-N).  $^1H$ -NMR ( $\delta$  ppm): 2.49 (DMSO), 4.04 (CH<sub>2</sub>), 4.67 (CH), 5.3 (OH), 6.82-8.1 (CH, Benzene), 13.14 (NH), 4.2 (NH tetrazole).  $^{13}C$ -NMR (125 MHz,  $\delta$  ppm): 182.1 (C=O, Carbonyl), 138.3-103.7 (C-benzene), 156, 158 (C-OH), 40.4 (DMSO), 69.06 (CH aliphatic), 70.01 (CH<sub>2</sub> aliphatic).

The prepared compounds insoluble in hexane, petroleum ether, diethyl ether, and acetone but shows a good solubility in solvent DMF & DMSO. Some of them have partial solubility in water, ethanol, and ethyl acetate. Solubility properties of prepared compounds in different solvents (H<sub>2</sub>O, petroleum ether, ethanol, CH<sub>2</sub>Cl<sub>2</sub>, ether, DMSO, hexane, ethyl acetate, acetone, and DMF) are listed in Table 2.

**TABLE 2** Solubility for compounds S1-S9 using different solvents


Compound	DMSO	DMF	DCM	Pet. ether	Ethyl acetate	Acetone	Di ethyl ether	H <sub>2</sub> O	Hexane	EtOH
S1	+	+	-	Partial	Partial	partial	-	+	Partial	+
S2	+	+	+	-	+	-	-	Partial	-	Partial
S3	+	+	-	Partial	Partial	Partial	-	+	-	+
S4	+	+	-	-	+	+	-	+	-	Partial
S5	+	+	+	-	Partial	+	-	Partial	Partial	+
S6	+	+	Partial	Partial	+	Partial	-	+	Partial	Partial
S7	+	+	+	-	-	+	-	Partial	-	+
S8	+	+	Partial	Partial	Partial	+	-	Partial	Partial	Partial
S9	+	+	+	Partial	+	Partial	-	+	Partial	Partial

### Biological activity

#### Anti-bacterial

The biological efficiency effect of bacteria (*E. coli*) and (*Staph. Aureu.*) was studied. The derivatives (S4-S9) have a good effectiveness in inhibiting the growth of (G-), the compounds (S3, S5-S9) have a good effectiveness in inhibiting bacteria (G+) with

compared of Cefotaxime Table 3 [24,26]. The prepared compounds possess good antibacterial activity, due to having functional groups and it has a wide importance in the clinical field, because of their resistance to chemical drugs and various antibiotics (Figures 1 and 2 and Table 3).

**FIGURE 1** *Staphylococcus aureus* activity test of the prepared compounds**FIGURE 2** *Klebsiella pneumoniae* activity test of the prepared compounds

**TABLE 3** Anti-bacterial activity for (S3-S9)

No. of Compound	Anti-bacterial activity test	
	<i>Klebsilla pneumonia</i> (G-)	<i>Staphylcoccus aureus</i> (G+)
Cefotaxime (Antibiotic) Standard	8	12
S3	7	13
S4	10	9
S5	22	17
S6	26	14
S7	12	24
S8	22	21
S9	11	23

*Antioxidant activity*


The DPPH method is used to study the activity of the synthesized compounds as antioxidant. Figure 3 and Table 4 show the results in comparison with ascorbic acid as control using 25, 50, and 100 mg/mL concentrations, the results shows that the 100 mg/mL concentration gave a good

inhibition zone compared to control. Compound S8 is the best one due to inhibiting the bacteria with IC<sub>50</sub> mg/mL 21.33. The existence of functional groups in the structure of synthesized compounds (S1-S9) might have an effect on the inhibition process. The order of compounds ordered compared to reference as follows:

S8>S2>S6>S5>S4>S9>S1>S7.

**TABLE 4** Anti-oxidants activity for (S1-S9)

Compound No.	Inhibition %			
	25 mg/mL	50 mg/mL	100 mg/mL	IC50 mg/mL
S1	49.01	50.01	55.21	42.23
S2	49.05	55.12	58.6	24.45
S3	46.13	52.11	60.02	43.5
S4	48.04	53.05	57.12	36.36
S5	49.46	53.02	59.16	30.08
S6	54.76	55.83	60.77	27.92
S7	44.22	51.44	61.03	50.38
S8	48.06	58.56	60.91	21.33
S9	47.04	54.05	57.12	36.35
Ascorbic acid(STD)	46.12	60.14	65.01	28.72



**FIGURE 3** Standard DPPH method for synthesized derivatives S1-S9

## Conclusion

Series of new compounds containing 1, 2, 3-triazoles and tetrazole groups have been synthesized based on Cromoglicic Acid and characterized using various techniques. In addition, the antibacterial activity of these compounds was tested against some pathogenic bacteria species and the obtained results showed a good activity. Furthermore, the activity as antioxidant was studied using DPPH method, the results show that most of these compounds have good activity as antioxidant agent compared to the control.

## Acknowledgements

The authors thank their universities for their support.

## Conflict of Interest

The authors declare that they have no conflict of interest.

## Orcid:

Hayfaa A. Mubarak:

<https://orcid.org/0000-0002-1279-6929>

Khalida A. Thejeel:

<https://orcid.org/0000-0002-0386-6446>

Mustafa M. Karhib:

<https://orcid.org/0000-0002-9261-7096>

Mohanad Mousa Kareem:

<https://orcid.org/0000-0003-4931-5524>

## References

- [1] D.J. Newman, G.M. Cragg, Natural products as sources of new drugs over the last 25 years, *J. Nat. Prod.*, **2007**, *70*, 461–477. [[crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [2] H. Cairns, C. Fitzmaurice, D. Hunter, P.B. Johnson, J. King, T.B. Lee, G.H. Lord, R. Minshull, J.S.G. Cox, Synthesis and structure-activity relations of disodium cromoglycate and some related compounds, *J. Med. Chem.*, **1972**, *15*, 583–589. [[crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [3] A. Gaspar, M.J. Matos, J. Garrido, E. Uriarte, F. Borges, Chromone: a valid scaffold in medicinal chemistry, *Chem. Rev.*, **2014**, *114*, 4960–4992. [[crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [4] J.S. Choi, J.K. Kim, Y.J. Yang, Y. Kim, P. Kim, S.G. Park, E.Y. Cho, D.H. Lee, J.W. Choi, Identification of cromolyn sodium as an anti-fibrotic agent targeting both hepatocytes and hepatic stellate cells, *Pharmacol. Res.*, **2015**, *102*, 176–183, [[crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [5] T.M.K. Motawi, Y. Bustanji, S.A. El-Maraghy, M.O. Taha, M.A. Al Ghusein, Naproxen and cromolyn as new glycogen synthase kinase 3 $\beta$  inhibitors for amelioration of diabetes and obesity: an investigation by docking simulation and



- subsequent in vitro/in vivo biochemical evaluation, *J. Biochem. Mol. Toxicol.*, **2013**, *27*, 425-436. [[crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [6] E.J. Phua, X. Lopez, J. Ramus, A.B. Goldfine, Cromolyn sodium for insulin-induced lipoatrophy: old drug, new use, *Diabetes Care*, **2013**, *36*, e204-e205. [[crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [7] S.K. Sharma, S. Kumar, K. Chand, A. Kathuria, A. Gupta, R. Jain, An update on natural occurrence and biological activity of chromones, *Curr. Med. Chem.*, **2011**, *18*, 3825-3852. [[crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [8] K.C. Majumdar, K. Ray, S. Ganai, T. Ghosh, Catalyst-Free 1,3-Dipolar Cycloaddition: An Efficient Route for the Formation of the 1,2,3-Triazole-Fused Diazepinone Framework, *Synthesis*, **2010**, *5*, 858-862. [[crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [9] J. Krim, B. Sillahi, M. Taourirte, E.M. Rakib, J.W. Engels, Microwave-assisted click chemistry: synthesis of mono and bis-1,2,3-triazole acyclonucleoside analogues of Acyclovir via copper(I)-catalyzed cycloaddition, *Arkivoc*, **2009**, *8*, 142-152, [[crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [10] S. Sajjadifar, H. Hamidi, K. Pal, Revisiting of Boron Sulfonic Acid Applications in Organic Synthesis: Mini-Review, *J. Chem. rev.*, **2019**, *1*, 35-46. [[crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [11] H.S. Mohamed, Z.S. Hamza, A.M. Nagdy, H.R. Abd El-Mageed, Calculations of Synthesized Triazolo Pyrimidine Derivatives: A Review, *J. Chem. rev.*, **2022**, *4*, 156-190. [[crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [12] J. Gujar, B. Londhe, R. Zambare, R. Kavade, M. Shingare, Glycine: An efficient catalyst for the synthesis of tetra-substituted imidazole derivatives in aqueous medium, *J. Appl. Organomet. Chem.*, **2021**, *1*, 134-142. [[crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [13] Y. Zhu, X. Siwei, J.A. Maguire, N.S. Hosmane, Application of cycloaddition reactions to the syntheses of novel boron compounds, *Molecules*, **2010**, *15*, 9437-9449, [[crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [14] A. Hassan Madloum, H. Shkyair Lihumis, Synthesis and characterization of new amide drug from cromoglicic acid and study of their possible biological activity, *J. Med. Chem. Sci.*, **2023**, *6*, 9-19, [[crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [15] H.A. Mubarak, A. A. Hussein, W. A. Jawad, M.M. Karhib, N. Abd Alrazzak, M. M. Kareem, A. Naje, Synthesis and characterization of new 4,6-dimethoxy-1H-indole derivatives as antibacterial and antitumor agents, *Eurasian Chem. Commun.*, **2023**, *5*, 411-424. [[crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [16] C.H. Fanta, "Asthma", *N. Engl. J. Med.*, **2009**, *360*, 1002-1014. [[crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [17] H.J. Schwartz, M. Blumenthal, R. Brady, S. Braun, R. Lockey, D. Myers, L. Mansfield, M. Mullarkey, G. Owens, P. Ratner, L. Repsher, A comparative study of the clinical efficacy of nedocromil sodium and placebo. How does cromolyn sodium compare as an active control treatment? *Chest*, **1996**, *109*, 945-952. [[crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [18] I. Wilkening, G. del Signore, C.P. Hackenberger, Phosphoramidate peptide synthesis by Staudinger reactions of silylated phosphinic acids and esters, *ChemComm.*, **2011**, *47*, 349-351. [[crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [19] B. Vhanale, D. Kadam, A. Shinde, Synthesis, spectral studies, antioxidant and antibacterial evaluation of aromatic nitro and halogenated tetradentate Schiff bases, *Heliyon*, **2022**, *8*, e09650. [[crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [20] C. Valgas, S.M.D. Souza, E.F. Smânia, A. Smânia Jr, Screening methods to determine antibacterial activity of natural products, *Braz. J. Microbiol.*, **2007**, *38*, 369-380. [[crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
- [21] A.A. Ibrahim, M.M. Kareem, T.H. Al-Noor, T. Al-Muhimeed, A.A. AlObaid, S. Albukhaty, G.M. Sulaiman, M. Jabir, Z.J. Taqi, U.I. Sahib, Pt(II)-ThioCarbohydrazone Complex as

Cytotoxic Agent and Apoptosis Inducer in Caov-3 and HT-29 Cells through the P53 and Caspase-8 Pathways, *Pharmaceuticals*, **2021**, *14*, 509. [[crossref](#)], [[Google Scholar](#)], [[Publisher](#)]

[22] L.N. Khanal, K.R. Sharma, Y.R. Pokharel, S.K. Kalauni, Phytochemical analysis and in vitro antioxidant and antibacterial activity of different solvent extracts of beilschmiedia roxburghiana Nees Stem Barks, *Sci. World J.*, **2022**, *2022*, 6717012, [[crossref](#)], [[Google Scholar](#)], [[Publisher](#)]

[23] T.S. Kadhim, M.M. Kareem, A.J. Atiyah, Synthesis, characterization and investigation of antibacterial activity for some new functionalized luminol derivatives, *Bull. Chem. Soc. Ethiop.*, **2023**, *37*, 159-169. [[crossref](#)], [[Google Scholar](#)], [[Publisher](#)]

[24] A.A.H. Ammar, M.M. Kareem, Synthesis of biological active compounds based on derivatives of maleimide, *AIP Conference Proceedings*, **2022**, *2547*, 040005. [[crossref](#)], [[Google Scholar](#)], [[Publisher](#)]

[25] A.F. Hasan, M.M. Kareem, M.N. Al-Baiati, Synthesis a novel nano co-polymer and using as carrier drug system, *Int. J. Pharm. Res.*, **2020**, *12*, 850-589. [[crossref](#)], [[Google Scholar](#)], [[Publisher](#)]

[26] A. Ahmed, I.Y. Majeed, N. Asaad, R.M. Ahmed, G.M. Kamil, S. Abdul Rahman, Some 3,4,5-trisubstituted-1,2,4-triazole synthesis, antimicrobial activity, and molecular docking studies, *Egypt. J. Chem.*, **2022**, *65*, 395-401. [[crossref](#)], [[Google Scholar](#)], [[Publisher](#)]

**How to cite this article:** Hayfaa A. Mubarak, Khalida A. Thejeel, Mustafa M. Karhib, Mohanad Mousa Kareem\*. Synthesis, characterization, and evaluation of antibacterial and antioxidant activity of 1, 2, 3-triazole, and tetrazole derivatives of cromoglicic acid. *Eurasian Chemical Communications*, 2023, 5(8), 691-700. **Link:** [https://www.echemcom.com/article\\_170232.html](https://www.echemcom.com/article_170232.html)